TABLE 1.
Subcohort and subgroup (no. of subjects) | Total no. of leukocytes | % of indicated cell typea
|
|||||||
---|---|---|---|---|---|---|---|---|---|
Lymphocytes | NK cells | T lymphocytes | CD4+ T lymphocytes | CD8+ T lymphocytes | CD4+ HLA- DR+ T cells | CD4+ CD38+ T cells | CD8+ CD38+ T cells | ||
A | |||||||||
NI (n = 32) | 6,175 ± 1,584 | 37.9 ± 7.1 | 13.0 ± 7.5 | 69.8 ± 8.5 | 43.6 ± 7.3 | 22.7 ± 6.0 | 12.8 ± 5.8 | ND | ND |
AS (n = 18) | 7,483 ± 1,879 | 35.9 ± 8.2 | 12.5 ± 8.8 | 70 ± 8.5 | 42.6 ± 6.9a | 24.2 ± 5.2 | 20.6 ± 8.0a | ND | ND |
OL (n = 14) | 7,029 ± 2,535 | 36.6 ± 5.3 | 12.8 ± 9.7 | 74.0 ± 9.0 | 48.9 ± 9.2a | 23.6 ± 4.9 | 33.8 ± 11.8a | ND | ND |
HT (n = 42) | 6,617 ± 1,865 | 39.1 ± 7.1 | 7.9 ± 4.9a | 78.5 ± 7.2ab | 48.3 ± 10.3ab | 28.6 ± 9.2abc | 40.4 ± 16.8a | ND | ND |
B | |||||||||
NI (n = 16) | 6,480 ± 1,759 | 40.8 ± 5.9 | 9.2 ± 6.4 | 69.0 ± 8.4 | 43.7 ± 7.5 | 24.0 ± 5.3 | 12.1 ± 4.9 | 24.4 ± 9.5 | 63.7 ± 18.0 |
AS (n = 22) | 6,800 ± 1,511 | 36.4 ± 6.6 | 12.2 ± 4.9cd | 69.7 ± 5.9 | 41.2 ± 7.6 | 26.9 ± 5.4 | 13.2 ± 3.3 | 22.6 ± 6.8 | 53.3 ± 10.7 |
OL (n = 13) | 6,538 ± 1,752 | 40.7 ± 6.9 | 7.1 ± 3.7 | 74.2 ± 6.3 | 48.0 ± 5.9 | 27.4 ± 8.2 | 17.8 ± 10.4 | 22.6 ± 6.4 | 54.5 ± 14.3 |
HT (n = 12) | 6,954 ± 1,712 | 37.5 ± 8.0 | 8.0 ± 5.7 | 77.2 ± 6.8ab | 52.3 ± 8.5abc | 23.5 ± 7.9 | 35.3 ± 16.2abc | 15.3 ± 3.9 | 54.9 ± 7.3 |
a, b, c, and d, significantly different from values for NI, AS, OL, and HT, respectively, at a P of <0.05. ND, not determined. Results are expressed as mean percentages±standard deviations.